Atara Biotherapeutics Inc

ATRA

Add to Watchlist

9.580USD

-0.010-0.10%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Atara Biotherapeutics Inc's Score

Industry at a Glance

Industry Ranking

133 / 382

Overall Ranking

262 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Atara Biotherapeutics Inc Highlights

StrengthsRisks

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 1308.75% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Undervalued

The company’s latest PE is -6.78, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.70M shares, decreasing 14.85% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 30.04K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 9.64.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

11.667

Target Price

+21.65%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Atara Biotherapeutics Inc is 7.13, ranking 123 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 516.00K, representing a year-over-year decrease of 99.47%, while its net profit experienced a year-over-year decrease of 110.91%.

Score

Industry at a Glance

Previous score

7.13

Change

0



Financials

4.64

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.98

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.06

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.82

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.17

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Atara Biotherapeutics Inc is 7.36, ranking 122 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -6.78, which is -417.10% below the recent high of 21.51 and -798.97% above the recent low of -60.98.

Score

Industry at a Glance

Previous score

7.36

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 133/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Atara Biotherapeutics Inc is 6.50, ranking 330 out of 382 in the Biotechnology & Medical Research industry. The average price target is 17.00, with a high of 18.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

6.50

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Atara Biotherapeutics Inc is 6.75, ranking 162 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 13.18 and the support level at 5.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.72

Change

0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Atara Biotherapeutics Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 43.48%, representing a quarter-over-quarter decrease of 28.53%. The largest institutional shareholder is James Simons, holding a total of 30.04K shares, representing 0.35% of shares outstanding, with 35.47% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Panacea Venture

1.63M

+18.87%

Adiumentum Capital Fund I LP

1.28M

+13.33%

EcoR1 Capital, LLC

573.18K

--

Redmile Group, LLC

441.70K

--

Mackenzie Financial Corporation

58.67K

-8.07%

Marshall Wace LLP

148.63K

+28.36%

GlobeFlex Capital, L.P.

77.22K

+399.57%

BlackRock Institutional Trust Company, N.A.

65.80K

+2.14%

Geode Capital Management, L.L.C.

62.38K

+3.06%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Atara Biotherapeutics Inc is 2.51, ranking 214 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is -0.10. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Atara Biotherapeutics Inc

ATRA

6.09 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment